Kempharm Assets Non Current Trend from 2010 to 2021

KMPH -  USA Stock  

USD 10.75  0.24  2.18%

Kempharm Assets Non Current are increasing over the last several years with slightly volatile swings. Assets Non Current are estimated to finish at about 3.7 M this year. During the period from 2010 to 2021 Kempharm Assets Non Current regressed destribution of quarterly values had coefficient of variationof 103.28 and r-squared of  0.22. Kempharm Selling General and Administrative Expense is most likely to increase significantly in the upcoming years. The last year's value of Selling General and Administrative Expense was reported at 7.92 Million. The current Weighted Average Shares is estimated to increase to about 4.3 M, while Consolidated Income is projected to decrease to (13.8 M).

Search Historical Trends 

 
Refresh
Check Kempharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kempharm main balance sheet or income statement drivers, such as Gross Profit of 14.6 M, Interest Expense of 4.7 M or Operating Expenses of 26.1 M, as well as many exotic indicators such as Asset Turnover of 1.26, Current Ratio of 1.14 or Gross Margin of 0.89. Kempharm financial statements analysis is a perfect complement when working with Kempharm Valuation or Volatility modules. It can also supplement various Kempharm Technical models. Please see the analysis of Kempharm Correlation against competitors.

Kempharm Quarterly Assets Non Current

2.71 MillionShare

Kempharm Assets Non Current Breakdown

Showing smoothed Assets Non Current of Kempharm with missing and latest data points interpolated. Amount of non-current assets; for companies that operate a classified balance sheet. Calculated as the different between Total Assets Total Assets and Current Assets Current Assets.Kempharm's Assets Non Current historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kempharm's overall financial position and show how it may be relating to other accounts over time.
Assets Non Current10 Years Trend
Increasing
Slightly volatile
 Assets Non Current 
Share
      Timeline 

Kempharm Assets Non Current Regression Statistics

Arithmetic Mean 2,975,034
Geometric Mean 1,614,636
Coefficient Of Variation 103.28
Mean Deviation 2,158,946
Median 3,025,000
Standard Deviation 3,072,469
Range 10,140,618
R-Value 0.46
R-Squared 0.22
Significance 0.13
Slope 395,593

Kempharm Assets Non Current History

20143.4 M
2015512 K
201610.5 M
20176.6 M
2018M
20193.5 M
20202.8 M
20213.7 M

About Kempharm Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Kempharm income statement, its balance sheet, and the statement of cash flows. Kempharm investors use historical funamental indicators, such as Kempharm's Assets Non Current, to determine how well the company is positioned to perform in the future. Although Kempharm investors may use each financial statement separately, they are all related. The changes in Kempharm's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Kempharm's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Kempharm Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Kempharm. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Assets Non Current2.8 M3.7 M
Average Assets10.9 M11.2 M
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Kempharm without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Comparator Now

   

Portfolio Comparator

Compare the composition, asset allocations and performance of any two portfolios in your account
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kempharm using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Kempharm Correlation against competitors. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Kempharm Stock analysis

When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.